1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

DSCSA Pilot Finds Blockchain Feasible For Meeting Track-And-Trace Requirements

 
• By Joanne S. Eglovitch

A pharmaceutical industry consortium gives the thumbs up for using blockchain technology to track and trace products through the supply chain to meet DSCSA mandate, yet says new standards are necessary.

Block chain concept - Chain consists of network connections
Pharma Industry Favors Blockchain Technology For Tracing Drugs Through Supply Chain • Source: Shutterstock

Some major pharmaceutical companies say that blockchain technology is a feasible data architecture system to track pharmaceutical products through the supply chain, yet in order to ensure its successful use, different blockchain systems need to be compatible. There also need to be new standards on how to communicate product identifier status and recalls through the blockchain.

These recommendations emerged from a pilot project that explored the feasibility of using blockchain technology. The 25 participants in the pilot represented a broad swath of industry stakeholders, including 10 manufacturers: Eli Lilly & Co., Amgen Inc., Endo Ventures Ltd., Genentech Inc.Gilead Sciences Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.